Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15894567 | 0.86 | CYP3A4 (0.42) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL1760529 | 0.85 | CA1 (0.70) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL11652210 | 0.81 | CA1 (0.73) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL4402447 | 0.81 | CA1 (0.52) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL1977309 | 0.81 | HTR2B (0.42) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL17281733 | 0.80 | CA1 (0.56) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL30467045 | 0.79 | GABRA1 (0.65) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL6943696 | 0.79 | GABRA1 (0.65) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL13773190 | 0.78 | GABRA1 (0.64) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL13997556 | 0.77 | GABRA1 (0.75) | CA1CA2GABRA1GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714175-B2 | Production method of aromatic hydroxide | SUMITOMO CHEMICAL COMPANY, LIMITED (JO) | 2010-05-11 | — | — | US | disclosed |
| US-20090318736-A1 | Production method of aromatic hydroxide | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1601641-A4 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1587783-A4 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1601641-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1587783-A2 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | KARO BIO AB (SE) | 2004-09-16 | — | — | US | disclosed |
| US-20040176425-A1 | Cycloalkyl containing anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004066929-A2 | CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067482-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-0031954-A2 | Sulphonamides, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
| US-4228297-A | Process for the production of hydroxyalkylphenyl derivatives | CIBA-GEIGY CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318736-A1 | Production method of aromatic hydroxide | PAH, AHR, HRH3 | CA1 2278/4885CA2 533/4885GABRA1 2734/4885 |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | TSHR, TRHR, THRA | CA1 4612/4885CA2 4691/4885GABRA1 643/4885 |
| US-20040176425-A1 | Cycloalkyl containing anilide ligands for the thyroid receptor | TSHR, THRB, TRHR | CA1 4590/4885CA2 4510/4885GABRA1 495/4885 |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | CA1 4829/4885CA2 4524/4885GABRA1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.